Filing identity and reporting period
Important entity mismatch: The supplied filing is Silverback Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2022—not a 10-Q filed by ARS Pharmaceuticals, Inc. Silverback proposed to acquire ARS Pharma in a merger.
Business context
Silverback was a pre-revenue biopharmaceutical company. After discontinuing clinical programs SBT6050 and SBT6290 in March 2022, it focused resources on SBT8230 and discovery programs. In connection with the proposed merger, Silverback was winding down research and development and pursuing sales of legacy assets.
Financial results and liquidity
- Revenue: No product revenue; the filing says the company had never generated revenue from product sales.
- Quarter ended September 30, 2022: Operating expenses were $18.9 million, down 16% year over year; net loss was $17.9 million, compared with $22.7 million. Basic and diluted loss per share was $0.50.
- Nine months ended September 30, 2022: Operating expenses were $63.4 million, down 4%; net loss was $61.9 million, compared with $66.0 million. Basic and diluted loss per share was $1.76.
- Expense drivers: Quarterly R&D expense fell 47% to $8.4 million as programs wound down. G&A rose 46% to $10.3 million, largely due to merger-related professional fees and severance.
- Cash flow: Net cash used in operations was $51.5 million for the first nine months, versus $45.5 million in 2021. Cash, cash equivalents and restricted cash declined $50.8 million to $203.5 million.
- Cash and investments: At September 30, cash, cash equivalents and investments totaled approximately $266.6 million; including $0.25 million of restricted cash, the total was approximately $266.9 million. Investments included U.S. Treasury securities with $1.6 million of unrealized losses.
- Balance sheet and debt: Total assets were $271.1 million, liabilities $4.0 million, and stockholders’ equity $267.1 million. The term loan had been fully repaid in 2021; no term-loan balance was reported.
- Margins: Not meaningful for this pre-revenue company; the filing provides no product sales or gross margin.
Material changes, outlook and risks
- Silverback reported that available cash, cash equivalents and restricted cash were sufficient for anticipated needs for 12 months after the financial statements were issued, while also expecting continuing operating losses.
- The July 2022 merger agreement contemplated ARS Pharma surviving as a wholly owned subsidiary. Based on an estimated $254 million of Silverback net cash at closing and an exchange ratio of approximately 1.1819, former ARS Pharma equity holders were expected to own about 62% and former Silverback holders about 38% of the combined company, on a fully diluted basis. The merger was subject to closing conditions, including Silverback stockholder approval.
- An October 25, 2022 amendment raised the permitted maximum Silverback net cash at closing from $255 million to $265 million; the minimum remained $210 million. The filing anticipated a fourth-quarter 2022 closing, but completion was not assured.
- Silverback had reduced its workforce by approximately 78% by September 30 and expected another 17% reduction by closing. It recorded $5.8 million of July-plan severance costs in the quarter and anticipated an additional $7.2 million in cash severance charges if the merger closed.
- Management expected R&D expense to decrease during the remainder of 2022 as activities wound down; G&A was expected to remain flat or increase because of merger and asset-sale work. Silverback sold equipment for net proceeds of $1.3 million, recording a $1.1 million loss, and agreed to sell certain linker-technology rights for $0.2 million after quarter-end.
- Risks include merger failure or delay, termination fees, asset sales not completing on favorable terms, the possibility of liquidation or another strategic transaction, and a securities class action alleging misleading statements about discontinued SBT6050. The company said the lawsuit’s potential loss could not be reasonably estimated and recorded no liability.
- COVID-19-related uncertainty included increased costs and possible delays in obtaining animals for preclinical studies. Management reported disclosure controls and procedures were effective at the reasonable-assurance level.
Most important facts for investors to verify
- Confirm the issuer: this is Silverback Therapeutics’ filing, not ARS Pharmaceuticals’ filing.
- Check the merger’s actual completion status, final exchange ratio, closing net cash and resulting ownership against subsequent filings.
- Verify the company’s cash and investment balances, ongoing cash burn, transaction costs and severance requirements.
- Review the outcome and any subsequent updates to the SBT6050 securities class action.
- Confirm whether legacy asset divestitures occurred and what proceeds, if any, were included in merger-related net cash calculations.